Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.

Key facts

Study ID

NCT00002721

Run by

University of New Mexico

People needed

18

Starts

1995-03-01

Expected to finish

2013-06-01

Last updated by the study team

2014-05-21

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• University of New Mexico Cancer Research & Treatment Center — Albuquerque, New Mexico, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.